Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials

Abstract

-keung Chow , Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Pnp(2017Pnp( ), doi: 10.1016Pnp( /j.pnpbp.2017 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.A C C E P T E D M A N U S C R I P T Aripiprazole was associated with lower relapse rates in bipolar mania when used in combination versus a placebo in maintenance therapy (odds ratio: 0.522, p<0.029). ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P TAripiprazole was also associated with higher levels of high density lipoprotein, lower dropout rates, but no difference in extrapyramidal symptoms in the maintenance phase versus a placebo or in comparison with other medications (haloperidol or lithium). Our results suggest that aripiprazole is effective and safe in treating bipolar mania. Further trials are necessary to evaluate the efficacy and tolerability versus other medications.

Sex-Specific Associations Between Bipolar Disorder Pharmacological Maintenance Therapies and Inpatient Rehospitalizations: A 9-Year Swedish National Registry Study

“…We found aripiprazole to be significant only among females for reducing the rate of either bipolar or psychiatric rehospitalizations; though in our sensitivity analyses with patients with non-bipolar rehospitalizations excluded or with rehospitalizations restricted to manic, depressive, or mixed episodes, aripiprazole reached significance among either sex. These findings are then in line with another RCT metaanalysis which found no significant sex-related differences for aripiprazole in preventing manic or depressive relapses (54). Aripiprazole has been suggested as an adjunct for the management of comorbid borderline personality disorder (36); a characteristic seen more often among females (27,30).…”

Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

“…Aripiprazole acts as a stabilizer of the dopamine-serotonin system. Its use was authorized for the treatment of schizophrenia in 2002 (266); in 2006 it was approved to treat bipolar disorder (mania or mixed episodes) (267), and major depressive disorder (as adjunctive drug) (268). In 2009 it was finally approved for the treatment of autism-related irritability (269).…”

Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure

“…The atypical antipsychotic aripiprazole is approved by the European Medicines Agency for treatment of schizophrenia as well as for treatment of moderate to severe manic episodes of bipolar I disorder [8][9][10][11].…”